BeOne Medicines reports 29% revenue growth in second quarter, driven by Brukinsa

BeOne Medicines reported second-quarter 2026 product revenue of $1.7 billion, a 29% increase from the same period last year, driven largely by continued growth in its blood cancer therapy Brukinsa (zanubrutinib), the company announced today in a news release.

BeOne Medicines is a global oncology company that manufactures cancer therapies, including Brukinsa, a Bruton's tyrosine kinase, or BTK, inhibitor. Brukinsa is used to treat chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and other blood cancers. The company also markets Tevimbra (tislelizumab), a PD-1 inhibitor used across many solid tumor types.

According to the release, Brukinsa generated $1.2 billion in global sales during the quarter, up 31% from a year earlier. U.S. sales of the drug totaled $893 million, also up 31%. Tevimbra brought in $229 million globally, up 18%. Gross margin on product sales rose to 90%, up from 87% a year earlier. BeOne attributed the increase to a higher sales mix of Brukinsa and to manufacturing efficiencies for both Brukinsa and Tevimbra.

The company reported that GAAP net income for the quarter was $237 million, up $143 million from a year earlier, which the company attributed primarily to revenue growth and improved operating leverage.

BeOne raised its full-year 2026 revenue guidance to a range of $6.6 billion to $6.8 billion, up from its earlier forecast of $6.3 billion to $6.5 billion. The company said the increase reflects Brukinsa's leadership position in the U.S. and continued expansion in Europe and other markets outside the U.S.

The quarter also included a number of regulatory and clinical updates relevant to oncology treatment decisions. The FDA granted accelerated approval to Beqalzi (sonrotoclax) for adult patients with relapsed or refractory mantle cell lymphoma. Those patients must have already received at least two prior lines of therapy, including a BTK inhibitor. BeOne also reported positive topline results from the Phase 3 MANGROVE study. The study found that Brukinsa combined with rituximab showed superior progression-free survival compared with bendamustine plus rituximab in adults with previously untreated mantle cell lymphoma.

In addition, 78-month follow-up data from the Phase 3 SEQUOIA study continued to show a sustained progression-free survival benefit for Brukinsa in adults with treatment-naive chronic lymphocytic leukemia. BeOne presented that data at the American Society of Clinical Oncology and European Hematology Association annual meetings.

Tevimbra also received regulatory approval in Japan for first-line gastric cancer. And BeOne announced that full results from the Phase 3 HERIZON-GEA-01 study were published in the New England Journal of Medicine. That study evaluated Ziihera (zanidatamab) plus chemotherapy, with and without Tevimbra, against trastuzumab plus chemotherapy. It was tested as a first-line treatment for advanced or metastatic HER2-positive gastroesophageal adenocarcinoma.

BeOne also pointed to progress in earlier-stage cancer programs that could reach patients in coming years. The company started a Phase 3 study of its CDK4 inhibitor, BGB-43395, combined with letrozole. That combination is being tested as a first-line treatment for adults with HR-positive, HER2-negative metastatic breast cancer. BeOne also began a first-in-human study of BON-110, an antibody designed to target PD-1, VEGF-A and CTLA-4, in lung cancer. Separately, the FDA granted Orphan Drug Designation to BGB-58067 for adults with pancreatic ductal adenocarcinoma.

Looking at near-term milestones, BeOne expects to submit Brukinsa for approval in first-line mantle cell lymphoma in the U.S., Europe, China and Japan. The company also anticipates an FDA decision on Tevimbra for first-line HER2-positive gastric cancer. Both are expected in the second half of 2026. BeOne also expects Chinese regulatory decisions on Tevimbra and Ziihera in HER2-positive gastric cancer in the first half of 2027.

“These strong second-quarter results underscore our continued growth as a global oncology leader. Our foundational hematology franchise, led by BRUKINSA, continues to gain momentum as we advance one of the industry's deepest and most diverse pipelines. With differentiated capabilities spanning drug discovery, clinical development, manufacturing, and commercialization, we are well positioned for our next phase of global growth,” John V. Oyler, co-founder, chairman and CEO of BeOne, said in the release.